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Background: The hallmark of atherosclerosis is the accumulation of plaque in vessel walls. This process is initiated
when monocytic cells differentiate into macrophage foam cells under conditions with high levels of atherogenic
lipoproteins. Vulnerable plaque can dislodge, enter the blood stream, and result in acute myocardial infarction and
stroke. Imaging techniques such as cardiovascular magnetic resonance (CMR) provides one strategy to identify
patients with plaque accumulation.
Methods: We synthesized an atherosclerotic-targeting contrast agent (ATCA) in which gadolinium (Gd)-containing
endohedrals were functionalized and formulated into liposomes with CD36 ligands intercalated into the lipid
bilayer. In vitro assays were used to assess the specificity of the ATCA for foam cells. The ability of ATCA to detect
atherosclerotic plaque lesions in vivo was assessed using CMR.
Results: The ATCA was able to detect scavenger receptor (CD36)-expressing foam cells in vitro and were specifically
internalized via the CD36 receptor as determined by focused ion beam/scanning electron microscopy
(FIB-SEM) and Western blotting analysis of CD36 receptor-specific signaling pathways. The ATCA exhibited
time-dependent accumulation in atherosclerotic plaque lesions of ApoE −/− mice as determined using CMR. No
ATCA accumulation was observed in vessels of wild type (C57/b6) controls. Non-targeted control compounds,
without the plaque-targeting moieties, were not taken up by foam cells in vitro and did not bind plaque in vivo.
Importantly, the ATCA injection was well tolerated, did not demonstrate toxicity in vitro or in vivo, and no
accumulation was observed in the major organs.
Conclusions: The ATCA is specifically internalized by CD36 receptors on atherosclerotic plaque providing enhanced
visualization of lesions under physiological conditions. These ATCA may provide new tools for physicians to
non-invasively detect atherosclerotic disease.
Keywords: Atherosclerosis, Magnetic resonance imaging, Metallofullerenes, Contrast agent, Macrophage, CD36Background
Atherosclerotic cardiovascular disease results in close to
20 million deaths annually. A hallmark of the disease is
the accumulation of plaque lesions in blood vessel walls
which can rupture and result in acute myocardial infarc-
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reproduction in any medium, provided the orneeded to identify incipient disease, monitor disease pro-
gression, and pinpoint factors that predict catastrophic
ruptures.
At present, it is difficult for physicians to specifically
detect and quantify plaque lesion buildup in vessel walls.
Cardiovascular magnetic resonance (CMR) is one of sev-
eral techniques being investigated to identify plaque bur-
den in patients so that interventions can be conducted
before rupture occurs [1,2]. We have used novel gadolin-
ium (Gd)-containing C80 endohedrals (Trimetaspheres™,
TMS, Gd3N@C80) [3] as a platform to develop newal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CMR. The TMS-based molecules have 25 fold increased
relaxivity compared to other contrast agents, reduced
risk of metal toxicity, and can be customized to address
issues surrounding solubility, specificity, etc. [4]. TMS
were functionalized with highly specific ligands for the
scavenger receptor CD36 found on the surface of macro-
phage foam cells in plaque lesions [5]. It is demonstrated
that ATCA specifically bind to and are taken up within
foam cells in vitro and are able to detect lesions in
plaque-susceptible mice in vivo (Apolipoprotein E defi-
cient mice [ApoE −/−]). Thus, TMS can be targeted to
specific biomarkers in sufficient quantities to provide
enhanced imaging of atherosclerotic plaque under
physiological conditions. These results suggest that the
ATCA may be a new tool for detecting atherosclerotic
plaque.
Methods
ATCA synthesis, functionalization, and characterization
The method to synthesize the TMS uses an electric-arc
process to encapsulate Gd within a carbonaceous cage,
C80 [3], which was used as the starting material for the
ATCA. The molecular weight of TMS (1,446 Da) was
determined using matrix-assisted laser desorption/
ionization (MALDI) with a time-of-flight (TOF) mass
spectrometer. Elemental analysis determined that TMS
contains 10.15 ± 0.25 mM Gd which approximates the
value estimated from the molecular weight. No free Gd
(Gd outside the carbon cage) was detected using an
Arsenazo III colorimetric test [6] and ICP analysis of li-
quid after dialysis of the TMS. Further, atomic force mi-
croscopy (AFM) measurement of the TMS showed the
majority of the nanoparticles are 1.1-1.3 nm in height
with some particles approaching 3.0 nm to 4.0 nm, sug-
gesting minimal agglomeration and/or aggregation.
The ATCA was developed as shown in Additional
file 1 in which the TMS is functionalized with hydro-
philic and lipophilic groups [4] and incorporated into
liposomes [7]. The resulting liposome-TMS were formu-
lated with or without CD36 ligands intercalated within
the liposome bilayer membrane [5,8]. The ATCA was
characterized as seen in Additional file 2.
Cell culture
Foam cells were generated using oxidized-low density
lipoproteins (oxLDL) from human plasma as described
previously [9] and verified using oil red-o (ORO) stain-
ing [10]. The upregulation of CD36 expression in foam
cells was confirmed using both PCR and FACs analysis
with CD36-specific antibodies. As a control, the non
CD36-expressing cell line 3 T3-F442A pre-adipocytes
were used to detect non-specific binding. The U937 cells
and foam cells were examined for toxicity using up to100 μg/ml (five times the amount used for in vivo stud-
ies) for 10 days. No significant differences in cell viability
was observed with ATCA-treated cells compared to con-
trols (not shown) which further supports the observation
that derivatized fullerenes are not toxic in vitro [11,12].
Cells were treated with CD36-targeted or non-targeted
controls at various concentrations for 24 hrs, centrifuged
and the supernatant saved for Gd analysis. After a quick
wash the cell pellet was disrupted by sonication and
supernatant and cell pellet subjected to ICP analysis or
neutron bombardment (both methods gave similar
results; not shown) to determine Gd concentration as
described below.
Cell uptake of the ATCA revealed by FIB-SEM crossbeam
workstation
In order to examine cell uptake of the ATCA we used a
Zeiss FIB-SEM crossbeam workstation. Foam cells were
incubated with or without ATCA or non-targeted con-
trol (20 μg/ml) for various times (16, 36, 72 hrs). As a
control non-targeted ATCA were incubated for the same
times. In addition, non-foam cells were incubated with
ATCA for 24 hrs. Cells were washed and fixed using 1%
glutaraldehyde solution and 0.1 M cacodylate buffer for
2.5 hrs at room temperature. Samples were mounted on
a microscope slide covered in aluminum foil and sub-
jected to graded EtOH incubations (60%-100%/10 min
each) and stored in a desiccated environment until
microscopic analysis.
The mounted samples were put in the FIB-SEM cross-
beam workstation, while a focused ion beam (FIB) was
used to cut the cells and expose inner structure of the
cell. Simultaneously, scanning electron microscope
(SEM) was used to image the cross section milled via
FIB, this is capable because both the ion beam and elec-
tron beam can focus on the exactly same area. The FIB
was operated at 30 kV, 20 pA and SEM was operated at
1 kV to reduce potential beam charge and cell damage. A
secondary electron detector was used to reveal morphology
and energy. Additionally, the energy and angle selective
backscattered electron (EsB) detector was applied to detect
ATCA existence and spatial distribution with nanometer
level resolution inside the cells, since heavy element Gd-
containing C80 endohedrals will express themselves much
brighter in EsB images if TMS exists.
Western blotting and quantification of CD36-specific
phospho-signaling intermediates
To confirm the specificity of CD36 ligand binding on
the ATCA to the CD36 receptor and examine the
mechanisms underlying the interactions between the
ATCA and foam cells, Western blotting was used as
described previously [13]. Following ATCA challenge,
foam cells were lysed directly in boiling denaturing
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triton-X-100 (0.5%) and protease inhibitors. Proteins
were separated on a 10% gels in tris-glycine SDS running
buffer. Western blotting and image quantification was
performed using the Odyssey Imaging System (LI-COR
Biosciences). Band intensities were captured using the
Odyssey scanner and bands quantified by measuring the
number of pixels in each band using a box drawn for the
same area of measurement for each separate blot. Band
intensities were normalized for loading by dividing the
number of pixels in each band with the housekeeping
band intensity (β-actin) on the same blot.
Flow cytometry
In order to confirm the upregulation of CD36 expression
on foam cells, U937 cells (negative control) or PMA/
oxLDL-transformed cells (foam cells) were washed with
PBS/1% BSA, and blocked for 30 min at 4°C with a
1/500 dilution of normal human serum. The cells were
washed and incubated with FITC-labeled anti-, CD36-
FITC, or FITC-labeled isotype control (BD Biosciences;
10 μg/mL) for one hr. at 4°C. After three washes, cells
were resuspended in 400 μL of PBS. The mean intensity
of fluorescence was determined for at least 10,000 cells
using a FACScan flow cytometer (BD Biosciences). All
experiments were performed in duplicate.
CMR study
The lesions in arteries of ApoE −/− mice progress from
fatty streaks to foam cell-containing plaque in a similar
way as humans [14,15]. ApoE −/− mice (23 weeks; fe-
male) and non-diseased controls were anesthetized ini-
tially with isoflurane (3%) and oxygen (3 L/min) in an
induction chamber and kept under constant sedation
via a nose cone while monitoring vital statistics as
described [16]. Further details of the CMR are out-
lined in Additional file 3. CMR was performed
blinded by personnel with no knowledge of targeted
and non-targeted compounds. All animal studies
were approved by Wake Forest School of Medicine
Animal Care and Use Committee.
Signal enhancement measurement
Images acquired after the ATCA injection were exam-
ined for areas of hyper-intensity in the aorta wall
(selected at random). As a comparison whole aortas
were analyzed as described in Additional file 3. Regions
appearing hyper-intense after ATCA injection were
manually traced using ImageJ (nih.org). The contrast to
noise ratio was calculated using a reference region of
interest (ROI) next to the plaque lesion or of the whole
aorta. The same regions were traced in the pre-ATCA
injection image and in all the post-ATCA time point
images. The contrast to noise was calculated using thesame reference ROI and then the contrast-to-noise ratio
(CNR) values were normalized to the pre-CA CNR
value. The quantification of signal intensities were tabu-
lated and analyzed for all variables and expressed as
mean ± standard error (SE) from five separate animals
per group (Figure 1B and Figure 1C). The StatPlus
(Analyst Soft, 2011) software was used to evaluate a
two (group) × two (time) analysis of variance
(ANOVA) with repeated measures was evaluated to
analyze data. Tukey LSD post hoc tests were used to
examine pair-wise differences. Significance was set at
p < 0.05.Histology, immunohistochemistry, and Gd detection in
tissue
The aorta of each animal was removed and fixed in
Tissue-Tek OCT (Miles, Elkhart, IN) and frozen with li-
quid nitrogen. The tissue was sectioned onto siloconized
slides and histopathology assessed using hematoxylin for
assessing plaque accumulation [17,18]. To examine
CD36 and CD68 expression on macrophages in the
plaque lesions the tissue sections were fixed in Carnoys,
embedded in parafilm, and tissue sections placed on
microscopic slides and probed with antibodies to CD36
and CD68 (both from Serotec) followed by horseradish-
conjugated secondary antibodies and developed using
AEC as described previously [19,20]. As a control non-
specific, isotype-matched control antibodies (for CD36
and CD68) were used. Images were captured using a
camera-equipped Zeiss AXIO Observer. For tissue dis-
tribution of Gd, organs (or ATCA sample used to inject
to determine total Gd counts) were weighed and placed
in pyrex tubes and combusted to ash at 900°C for 1 hr.
The samples were again weighed and resuspended in
1.0 ml of 12 M (37%) HCl. The Gd was measured
using ICP and percent Gd in tissue calculated based
on the total amount of Gd in the ATCA sample
used for injections.
Toxicology evaluation
ApoE −/− were injected i.v. with PBS or 1,000 μg/100 μl
(10 times more than optimized for imaging studies) of
ATCA. Mice (four/group) were sacrificed at days two,
seven, and 14 and alanine aminotranferease (ALT) and
aspartate aminotransferase (AST) levels evaluated in
serum. The ALT and AST are transaminase enzymes that
leak out into the general circulation when the liver is
injured. In separate experiments, ATCA were injected as
above, tissue harvested at day seven, and subjected to
neutron bombardment or ICP for Gd quantification. An
aliquot of the ATCA (not injected) was measured
separately to determine the percentage cleared from
the mice.
Figure 1 (See legend on next page)
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Figure 1 ATCA can detect inflammatory plaque in vivo. ApoE−/− mice (23 wks; n=5/grp) were injected i.v. (100 μg/100 μl) with ATCA (top
and middle) or non-targeted control (bottom) and images acquired at the indicated times. Bar = 1.0 mm. Arrows indicate contrast agent binding
to the plaque. A. Representative images from two (ATCA) or one (control) different mice injected with ATCA. B, C. Quantification of signal
enhancement of ATCA. In B, the brightest voxels (approximately >10 spots/section) in the aorta wall from 5 separate animals were measured
excluding artifact. The ratio of the Signal Intensity (SI) of the brightest voxel in the aorta wall to the SI of the (non-affected) myocardium for each
time point was calculated. In C, the ratio of SI of the whole region lining the aorta wall to the SI of the (non-affected) myocardium was measured
and the average signal intensity was recorded for 5 separate slices from each time-point. The SI-enhanced/SI-myo ratio from each time point to
its pre scan SI-enhanced/SI-myo ratio were normalized (prescan values = 1). Data is expressed as mean of 5 CMR slices ± SD (n = 5; animals/grp;
* indicates significance (p<0.05). D. Plaque lesions express macrophages and CD36 receptors. Aortas were stained with H&E (left), rat anti-mouse
CD36 (middle), rat anti-mouse CD68 (bottom) or non-specific rat IgG (nsIgG). Peroxidase-conjugated anti-rat Abs were added and developed
using AEC. The brown staining represents CD36- or CD68-positive cells located in the plaque lesions. Results are representative of at least three
separate aortas.
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Plaque targeting contrast agents are selectively taken up
by foam cells through CD36 receptor
Atherosclerotic plaque have higher numbers of macro-
phage foam cells that express CD36 scavenger receptors
on their cell surface [21]. Given that the CD36 actively up-
take extracellular lipids into their cytoplasmic membraneU937+CD36
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Figure 2 A. Upregulation of CD36 receptors on foam cells. U937 cells
incubated with antibodies to CD36 or an isotype matched control. The gra
(±SD) and is representative of three separate experiments. B. Testing ATCA
foam cells (foam) using oxLDL and PMA as described. Cells were washed a
cells were washed with media and the supernatants (S) and pellets (P) sub
supernatant was calculated based on the total amount added to the cells.[22], we hypothesized that this may be a way to incorpor-
ate the ATCA contrast agent into foam cells in sufficient
enough quantities that CMR could be performed. Foam
cells were induced using PMA/oxLDL and the upregula-
tion of CD36 expression was confirmed using FACs ana-
lysis (Figure 2A). As seen in Figure 2B, ATCA had a
significant uptake into the CD36-expressing foam cells.-FITC  
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jected to ICP for Gd detection. The percentage of Gd in the pellet and
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geting moiety ligands (control) was not taken up within
the cells suggesting the CD36 receptor was responsible for
the uptake of the compounds within the cells. In data not
shown, there was no uptake in non-foam cell monocytes
or non-monocytic, tissue cells (3 T3).
We next used a FIB-SEM - to follow the ATCA in-
side foam cells and determine the length of time it
remains. Figure 3A-3H demonstrates that fullerene-basedArea of cut 
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Figure 3 A-H. ATCA are taken up by foam cells. Foam cells were incub
(A,B), 48 (C,D) or 72 (E,F) hrs, washed, fixed, and subjected to FIB-SEM. Left
electron detector after focused ion beam cut and the right column (B,D,F,H
and angle selective backscattered electron (EsB) detector for the same regi
but not in the non-targeted controls. In parallel, an aliquot of cells were us
cell death induced by ATCA addition compared to non-treated controls (ncompounds can be detected inside human foam cells. The
ATCA is shown to be more scattered inside the cell at earl-
ier time points (B,D) and begins to aggregate with lesser
amounts inside the cell at later time points (F) suggesting
cell excretion. The non-targeted control was not detected
inside the foam cells (G, H) further suggesting the specifi-
city of the ATCA for foam cells.
To definitively establish the specificity of ATCA bind-
ing to the CD36 receptor we used Western blotting andH 
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ated with ATCA (10 μg/ml; A-F) or non-targeted control (G,H) for 16
columns (A,C,E,G) shows the morphology images taken by secondary
) shows the corresponding material contrast images taken by energy
on. The foam cell-targeted ATCA are clearly revealed inside the cells
ed to measure cell viability by trypan blue exclusion and revealed no
ot shown).
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induced by ATCA treatment. Previous studies have
shown that Erk, Lyn, and JNK2 are activated by the
binding of oxLDL to CD36 receptors on macrophages
[23,24]. When foam cells were challenged with ATCA
there was a dose (Figure 4A) and time (Figure 4B)
dependent activation of these signaling molecules.
This provides definitive evidence that ATCA specific-
ally target foam cells through CD36 receptors.Figure 4 A,B. ATCA activate CD36-specific signaling intermediates. Fo
(A; dose response) for 10 min or with 10 μg/ml ATCA (B; time course) for vary
antibodies. Band intensities were quantified and the numbers represent the fo
which did not demonstrate any change upon ATCA challenge. Results are repATCA detect atherosclerotic plaque in vivo
We used ATCA to visualize atherosclerotic disease in
ApoE −/− mice [14]. As seen in Figure 1A (top and mid-
dle), mice injected i.v. with the ATCA had a striking
enhanced T1 image of the plaque attached in the mouse
aorta that could not be seen prior to injection. Of note is
the observation that the imaging agent accumulates over
time, suggesting it circulates through the blood for
periods long enough for biomarker targeting to occuram cells were incubated with or without varying concentrations of ATCA
ing times. Cells were lysed and Western blotted using phospho-specific
ld increase of each band compared to the housekeeping gene β-actin
resentative of three separate experiments.
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CD36 ligands demonstrated no accumulation in the vessel
walls of ApoE −/− mice (Figure 1A-bottom). Quantification
of the image intensity of ROI’s appearing after ATCA injec-
tion (Figure 1B) demonstrates accumulation of the com-
pounds occurs after 30 min; one and two hour time-points
demonstrated the optimal imaging time. When measuring
the entire aorta the normalized mean intensity was very
similar to what was observed in the bright spot ROI’s
(Figure 1C). This quantification clearly demonstrates the
ATCA significantly increases the contrast representing
plaque lesions.
Separate experiments were performed with non-
diseased animals. In these experiments the ATCA and
control were injected and the descending aorta imaged at
the same time points. As seen in the bottom panels wild-
type C57 mice did not demonstrate any signal enhance-
ment in the descending aorta further demonstrating the
specificity of the ATCA for plaque detection. These
results suggest the ATCA specifically detect disease-
induced plaque lesions that are not expressed in normal
vessel walls. Histochemical evaluation of each animal
revealed that plaque lesions were present in the diseased
animals (Figure 1D; left) with the accumulation of CD36-
and CD68-positive cells on the anterior portion of the
plaque lesions (Figure 1D; middle/bottom).Tracking the in vivo fate and toxicity of plaque-targeting
contrast agents
In order to determine the fate of the ATCA we per-
formed whole body scans after i.v. injection as described
above. In all experiments the injection was well tolerated
in each group of mice with no noticeable adverse reac-
tions observed. As determined using CMR, there was no
accumulation of any of the compounds in any major
organs (e.g. liver and kidneys) at the same time points
measured in the ApoE −/− mice (Figure 5A). To confirm
these results we performed ICP analysis on the organs of
these animals after seven days post injection. As seen in
Table 1 Gd was only detected in the liver and kidneys
demonstrating that approximately 85% of the ATCA is
excreted from the body at this time-point.
In separate experiments in which high concentra-
tions of ATCA were injected, there was no significant
increase in serum activity of ALT and AST between the
untreated and ATCA-treated animals indicating no
liver toxicity (Figure 5B). Thus, the ATCA do not affect
liver function and are mostly cleared from the body
within five days after injection.Discussion
The results presented here demonstrate that atheroscler-
otic plaque can be detected in vivo using targeted, Gd-based molecular imaging nanomaterials and standard
CMR techniques. Our rationale for developing ATCA
was driven by the need for new ways to diagnose blood
vessel plaque burden with existing technologies such as
CMR. It is well established that atherosclerotic plaque
express high levels of CD36 receptors for which ligands
have already been identified. Importantly, these recep-
tors normally and actively internalize the ligands
(oxLDL); a prerequisite for accumulation of sufficient
levels so that enhanced contrast can be observed. It is
shown that this strategy was successful in identifying
new ATCA which may provide new tools for physicians
to detect plaque buildup in patients.
Magnetic resonance imaging is one of many techni-
ques used to assess atherosclerotic plaque lesions in
patients [25,26]. We functionalized the TMS through the
addition of CD36 ligands which were hypothesized to
home to macrophage foam cells found in atherosclerotic
plaque [27-30]. Indeed, many studies have used this
strategy of targeting diagnostics to macrophages through
scavenger receptors as well as other macrophage-
expressed biomarkers through several techniques includ-
ing CMR [27,31-41]. For example, the Fayad group
investigated the ability of macrophage scavenger
receptor-targeted immunomicelles to assess macro-
phages in atherosclerotic plaque using CMR in vivo. The
targeted micelles increased the signal intensity of athero-
sclerotic aortas 79% in ApoE−/− mice compared with
only 34% using untargeted controls [27]. Others have
targeted macrophages through the use of Lyp-1 peptides
attached to a fluorescent dye [34]. Thus, targeting
macrophages in atherosclerotic lesions is a valid strategy
for developing diagnostics capable of detecting and
quantifying plaque lesions. The advantages of using the
CD36 receptor for targeting CMR contrast agents to
plaque is its well established connection in atheroscler-
osis [28,30], its high expression on plaque foam cells
[28], and its ability to be internalized upon ligand bind-
ing [42] which allows the accumulation of the ATCA
ligand even under physiological flow conditions as was
shown in Figure 1. The key limitation presently is the
lack of a specific biomarker (or biomarkers) for plaque
lesions that will not cross-react with other sites in the
body. An even more difficult challenge is identifying
vulnerable plaque biomarkers.
We used the Gd-containing TMS as they provide a
unique starting material for developing biomarker-
targeting diagnostics [43]. The TMS offers several advan-
tages over current Gd-based CMR contrast agents for
use as targeted diagnostics. First, the toxic Gd (in cage)
is separated from active targeting moieties (outside cage)
by the carbon shell. Adding targeting ligands/moieties to
current contrast agents may affect the ability of Gd to
become free of the compound. Of course, further studies
ATCA
kidney
liver
lungs
control
Pre 30 min 60 min 120 min
A
B Day 2 Day 7
Untreated Treated Untreated Treated
n Activity U/L n Activity U/L n Activity U/L n Activity U/L
Aspartate Amino Transferase  (AST) 4 27.5 (±9.2) 4 21.7 (±8.6) 4 20.5 (±3.2) 4 19.7 (±8.6) 
Alanine  Amino Transferase (ALT) 4 64.2 (±11.5) 4 52.7 (±7.7) 4 68.7 (±11.5) 4 62.9 (±7.7) 
n= Number of Mice evaulated in Duplicates
Figure 5 A. Plaque-targeting contrast agents do not accumulate in major organs. A representative plaque-targeting contrast agent and
non-targeted control was injected as above and the mouse placed supine for whole body scan. Results are representative of four separate mice.
B. C. ATCA does not accumulate in liver or induce toxicity. Mice were treated with or without 1000 μg/100 μl of ATCA via tail vein injection. Two
and six days later the serum was used for ALT and AST levels. Data is presented as an average of four (untreated) or four (treated) mice ± SD. No
increase in activity was observed between the untreated and treated samples. Activity is measure by Units/L obtained using linear regression
from a standard curve.
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others have not observed any toxicity of empty cage or
TMS (Figure 5) using several in vitro and in vivo assays
[12,44,45]. Second, the TMS are more sensitive than
existing contrast agents with three Gd/molecule com-
pared to one Gd/molecule in commercially availableTable 1 Total percent Gd in tissue
Day 7 (n=4)
Average SD
Liver 9% ±6%
Heart ND ND
Spleen ND ND
Kidney 3% ±2%
Lung ND ND
Total Gd in tissue was valuate compared to total Gd injected ND-none
detected.chelates [43]. Targeted imaging agents require strong
signals by which to report the presence of an agent at a
particular location. Third, the fullerene cage can be tar-
geted to disease biomarkers or encapsulated into lipo-
somes/micelles without compromising release of Gd
into the body; a strategy already being used for targeting
glioblastoma [46]. The chemistry for the addition of dif-
ferent moieties to the cage offers many possibilities for
not only biomarker targeting of plaque accumulation
but also detection of biomarkers associated with removal
of lesions (e.g. peptidoglycans) so that new tools for
evaluative diagnosis of this disease can be developed.
The specificity of the ATCA for targeting foam cells
through CD36 is demonstrated three separate ways.
First, ICP analysis of Gd within foam cells was con-
firmed in Figure 2B demonstrating that the CD36
ligand-decorated ATCA were significantly taken up
within foam cells while the non-targeted ATCA were
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that can be used to cut the cell open and detect nano-
materials, to further show the targeted ATCA is specific-
ally internalized within foam cells were levels begin to
diminish after 72 hrs. This suggests the cells remain
viable and can continue to exocytose as a normal macro-
phage would. Third, we show the targeted ATCA, and
not the non-targeted, specifically activate signal trans-
duction intermediates in the CD36 receptor pathway in-
cluding the ligand binding-dependent phosphorylation
of Erk, Lyn, and Jnk. Thus, the ATCA specifically detects
and is taken up by macrophage foam cells though the
CD36 receptor.
The use of ApoE −/− mice to study CMR contrast
agents has been described extensively [14,15]. We dem-
onstrate that the ATCA specifically recognize athero-
sclerotic plaque in diseased animals. No contrast was
observed with non-targeted controls or in ATCA-trea-
ted, non-diseased animals. The signal enhancement
occurs in a time-dependent fashion suggesting the foam
cells are actively internalizing the ATCA via the CD36
scavenger receptor. While it has been reported that the
lesion burden can vary among animals it was demon-
strated that each animal tested had high levels of plaque
lesions containing macrophages and CD36 receptors as
identified using histochemistry and immunohistochemis-
try (Figure 1D). While each animal was verified to con-
tain inflammation one limitation of this study was the
small numbers of animals used. We are in the process of
verifying these results in higher-order mammals (rab-
bits). The high power 7 T scanner used warrants further
validation of the ATCA in a more clinically relevant
scanner. However, the TMS have been studied in lower
field magnets and demonstrate similar relaxivity and
sensitivity [47,48].
Investigation of biocompatibility and biodistribution of
the TMS-based protein cages in vivo is critical for future
clinical translation. To this end, the studies examining
the toxicity of fullerenes on human systems are still
emerging and the subject of debate [44,49]. Several
in vivo publications suggest that (in general) fullerenes
show no overt signs of toxicity up to 2000 mg/kg [50,51]
and have been shown to extend the lives (11%) and im-
prove cognitive function of mice chronically treated with
these compounds [52]. More recently, rats given fuller-
enes in olive oil lived over 90% longer than control mice
[53]. We demonstrated that a single dose of ATCA,
given at a 100 fold concentration higher than that
needed for plaque imaging in vivo, caused no overt signs
of toxicity, does not accumulate in the liver, and does
not induce liver damage. These results are consistent
with the observation that TMS injected i.v. into mice is
passed through the kidney and into the urine (data not
shown). The ATCA is mostly cleared from the body afterseven days as demonstrated above. Similarly, the TMS
were recently shown to have a favorable toxicity profile
in vitro and in vivo [12]. Since it is anticipated that a
patient will only be given a single injection before
CMR is performed, these results are encouraging for
future studies in humans. However, more studies are
clearly needed to examine the long-term effects of
fullerenes on biological systems. Efforts are focused
on systematically identifying any acute and long-
term toxicity issues with ATCA.
Conclusions
This study describes the synthesis and testing of a new
class of ATCA based on a novel metallofullerene nano-
material. In vitro screening was used to select high relax-
ivity compounds that were taken up by foam cells via
the scavenger receptor CD36. The CD36 compounds
were shown to target inflammatory lesions in ApoE −/−
mice while the same compounds without the CD36
ligands did not. These and other similar studies dis-
cussed above suggest the rationale for targeting macro-
phage foam cell may provide physicians with new tools
for non-invasively diagnosing and quantifying otherwise
undetectable plaque lesions. These results also suggest
the TMS may serve as a platform to attach other bio-
markers to target and image disease-specific biomarkers.
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